End-of-day quote
Shenzhen S.E.
18:00:00 2024-05-13 EDT
|
5-day change
|
1st Jan Change
|
7.34
CNY
|
-0.68%
|
|
-2.65%
|
-35.50%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
4,833
|
6,010
|
7,931
|
7,632
|
6,362
|
5,853
|
Enterprise Value (EV)
1 |
4,703
|
6,032
|
6,890
|
7,889
|
3,753
|
4,813
|
P/E ratio
|
23.2
x
|
29.6
x
|
11.7
x
|
10.9
x
|
6.79
x
|
-25
x
|
Yield
|
0.69%
|
0.56%
|
1.3%
|
0.44%
|
4.85%
|
-
|
Capitalization / Revenue
|
2.43
x
|
2.49
x
|
1.91
x
|
1.79
x
|
0.91
x
|
2.41
x
|
EV / Revenue
|
2.36
x
|
2.5
x
|
1.66
x
|
1.85
x
|
0.54
x
|
1.98
x
|
EV / EBITDA
|
13.7
x
|
13.4
x
|
4.57
x
|
5.19
x
|
1.65
x
|
107
x
|
EV / FCF
|
182
x
|
-72.7
x
|
10.5
x
|
15.8
x
|
2.68
x
|
-6.12
x
|
FCF Yield
|
0.55%
|
-1.38%
|
9.48%
|
6.31%
|
37.3%
|
-16.3%
|
Price to Book
|
2.22
x
|
2.55
x
|
2.53
x
|
2.03
x
|
1.32
x
|
1.4
x
|
Nbr of stocks (in thousands)
|
515,224
|
514,527
|
514,357
|
514,268
|
514,297
|
514,298
|
Reference price
2 |
9.380
|
11.68
|
15.42
|
14.84
|
12.37
|
11.38
|
Announcement Date
|
19-03-21
|
20-04-28
|
21-04-27
|
22-04-29
|
23-03-22
|
24-03-22
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,990
|
2,414
|
4,155
|
4,268
|
6,970
|
2,428
|
EBITDA
1 |
344.5
|
450.5
|
1,509
|
1,521
|
2,280
|
44.92
|
EBIT
1 |
259.4
|
331.7
|
1,378
|
1,422
|
2,117
|
-141.5
|
Operating Margin
|
13.04%
|
13.74%
|
33.16%
|
33.32%
|
30.37%
|
-5.83%
|
Earnings before Tax (EBT)
1 |
298.7
|
328.8
|
1,356
|
1,384
|
2,065
|
-185.6
|
Net income
1 |
207.8
|
202.5
|
675.4
|
721
|
970.8
|
-234
|
Net margin
|
10.44%
|
8.39%
|
16.25%
|
16.89%
|
13.93%
|
-9.64%
|
EPS
2 |
0.4046
|
0.3946
|
1.318
|
1.364
|
1.821
|
-0.4550
|
Free Cash Flow
1 |
25.78
|
-82.95
|
653.2
|
498.1
|
1,401
|
-786.6
|
FCF margin
|
1.3%
|
-3.44%
|
15.72%
|
11.67%
|
20.1%
|
-32.4%
|
FCF Conversion (EBITDA)
|
7.48%
|
-
|
43.28%
|
32.76%
|
61.44%
|
-
|
FCF Conversion (Net income)
|
12.41%
|
-
|
96.72%
|
69.09%
|
144.28%
|
-
|
Dividend per Share
2 |
0.0650
|
0.0650
|
0.2000
|
0.0650
|
0.6000
|
-
|
Announcement Date
|
19-03-21
|
20-04-28
|
21-04-27
|
22-04-29
|
23-03-22
|
24-03-22
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
21.8
|
-
|
257
|
-
|
-
|
Net Cash position
1 |
129
|
-
|
1,041
|
-
|
2,609
|
1,040
|
Leverage (Debt/EBITDA)
|
-
|
0.0485
x
|
-
|
0.1691
x
|
-
|
-
|
Free Cash Flow
1 |
25.8
|
-83
|
653
|
498
|
1,401
|
-787
|
ROE (net income / shareholders' equity)
|
10.9%
|
10.7%
|
34.7%
|
28.9%
|
31.5%
|
-3.27%
|
ROA (Net income/ Total Assets)
|
5.21%
|
5.75%
|
17.8%
|
15.8%
|
16.8%
|
-1.13%
|
Assets
1 |
3,985
|
3,521
|
3,796
|
4,565
|
5,785
|
20,669
|
Book Value Per Share
2 |
4.230
|
4.580
|
6.110
|
7.300
|
9.360
|
8.110
|
Cash Flow per Share
2 |
0.9500
|
0.8600
|
4.180
|
1.170
|
6.760
|
3.170
|
Capex
1 |
124
|
140
|
258
|
226
|
428
|
331
|
Capex / Sales
|
6.23%
|
5.81%
|
6.2%
|
5.29%
|
6.14%
|
13.63%
|
Announcement Date
|
19-03-21
|
20-04-28
|
21-04-27
|
22-04-29
|
23-03-22
|
24-03-22
|
|
1st Jan change
|
Capi.
|
---|
| -35.50% | 517M | | -1.52% | 8.37B | | +10.68% | 5.84B | | +26.94% | 5.4B | | -5.09% | 4.37B | | -52.54% | 3.23B | | +14.18% | 2.8B | | +32.50% | 2.26B | | -6.47% | 2.22B | | -1.69% | 1.87B |
Diagnostic & Testing Substances
|